Stay updated on Trastuzumab-Emtansine & Atezolizumab in HER2+ LABC/MBC Clinical Trial
Sign up to get notified when there's something new on the Trastuzumab-Emtansine & Atezolizumab in HER2+ LABC/MBC Clinical Trial page.

Latest updates to the Trastuzumab-Emtansine & Atezolizumab in HER2+ LABC/MBC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe page has been updated to reflect a new study on Trastuzumab Emtansine in combination with Atezolizumab, with significant changes in the number of study locations and the estimated last update date. The study now includes 50 locations compared to the previous 108, and the last update is now estimated for February 2025.SummaryDifference29%
- Check44 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1.0%
- Check51 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check65 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check73 days agoChange DetectedThe type of intervention has been updated from version v2.13.3 to v2.14.0.SummaryDifference0.2%
- Check101 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.1%
Stay in the know with updates to Trastuzumab-Emtansine & Atezolizumab in HER2+ LABC/MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trastuzumab-Emtansine & Atezolizumab in HER2+ LABC/MBC Clinical Trial page.